Abstract Search

ea0099p92 | Endocrine-Related Cancer | ECE2024

How well does ‘real world’ management of Immune check point inhibitor induced hypophysits (ICI-Hp) reflect the European Society of Endocrinology (ESE) 2023 clinical practice guidelines (CPG)?: Experience from a single tertiary care centre

Mathara Diddhenipothage Shani Apsara Dilrukshi , Warden Jacqui , Herbert Katie , Pofi Riccardo , Coupe Nicholas , Payne Miranda , Tomlinson Jeremy W , Turner Helen

Introduction: Hypophysitis (Hp) is a serious adverse effect (AE) of Immune check-point inhibitor (ICI) therapy in malignancy. We evaluated 6 yeas of clinical expereince with ICI against the recent ESE CPG 2023 which provides practical guidance on the management of this condition based on up-to-date evidence.Methods: A quality improvement project (QIP) included all patients with ICI-Hp (n=17) referred to a dedicated Endocrine-ICI clinic (January ...

0 shares

Endocrine Abstracts

How well does ‘real world’ management of Immune check point inhibitor induced hypophysits (ICI-Hp) reflect the European Society of Endocrinology (ESE) 2023 clinical practice guidelines (CPG)?: Experience from a single tertiary care centre

BiosciAbstracts